The late-stage pipeline for non-Hodgkin’s lymphoma (NHL) contains a diverse range of mechanisms of action. 

Non-Hodgkin’s lymphoma treatment

The figure below displays ongoing trials for agents seeking a first approval in NHL. Of the seven therapies, two are targeting CD19 (Celgene’s lisocabtagene maraleucel and MorphoSys’ tafasitamab) while the remaining five each work against different targets. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Combination therapies are the norm in NHL treatment, and the pipeline reflects that as lisocabtagene maraleucel and Amgen’s Blincyto are the only therapies being investigated as monotherapies, while the remainder is being investigated in combination with other therapies. 

Roche’s Polivy (polatuzumab vedotin-piiq) was recently approved by the US Food and Drug Administration (FDA), in June 2019, in combination with bendamustine and rituximab. GlobalData believes TG Therapeutics’ U2 regimen (ublituximab + umbralisib) will be the next therapy to achieve an FDA approval, in 2020.

 Source: GlobalData © GlobalData

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CMR = complete metabolic response; DLT =dose-limiting toxicities ; EFS = event-free survival; ORR = overall response rate; OS = overall survival; PCD = primary completion date; PFS = progression-free survival; TLS = tumor lysis syndrome